CATEGORIES: Research

Quality of Life and CMT Research

by | Jul 7, 2014 | 4 comments

Did you know that 95% of clinical trials fail? There are multiple causes, most related to efficacy or safety, which obviously can be harmful and risky for patients. The risk-reward of enrolling in trials is a judgment call based on the devastating effects of disease related to quality of life (QoL) or life-threatening disease. With CMT, the risk-reward is more of a challenging question for many, as CMT in most cases is non-fatal. For many CMT patients, their condition is manageable and not worth the risk of potential harmful effects of drugs or other therapeutic options. However, many are terribly suffering and would benefit from participating in clinical studies that could have therapeutic benefits. In addition to safety and efficacy, the measurement of patient-reported outcomes is critical when clinical trials are developed for inherited neuropathies. It is well documented that for CMT (and many of the neuromuscular diseases), there are poor clinical outcomes measurement instruments and methods for validating the potential use of treatments for these diseases. HNF has developed two clinical studies that can increase the chances of successful future trials and ensure drug therapies will come to market for CMT.

Assuming the hurdles are overcome in the development of safe treatments, it’s still imperative to the success of therapy development to have valid primary and secondary outcomes measures.  Although there are some valid novel instruments such as, NIH’s PROMIS® and Neuro-QOL, in comparison to more established tools, such as the Child Health Questionnaire, Short Form- 12/36, and EQ-5D we still lack strong methods that measure QoL as well as outcomes measures for the disease.

Later this year, HNF will launch a health-related QoL clinical study in collaboration with three neuromuscular centers that will enhance clinical endpoints used for determining benefits or negative effects of potential treatments. Our goal is to develop a clear method for determining the clinical utility of potential treatments for CMT and related neuromuscular diseases. The study will be led by Dr. Renée J. Goldberg Arnold, PharmD, President and CEO, Arnold Consultancy & Technology LLC, NYC, where she develops and oversees outcomes research and affiliated software for industry and the federal government. Her special interest in evidence-based health derives from her research that deals with use of technology to collect and/or model real-world data for use in rational healthcare decision-making by healthcare practitioners and policy makers. Dr. Arnold’s academic titles include Adjunct Associate Professor, Master of Public Health (MPH) program, Department of Preventive Medicine at the Mount Sinai School of Medicine, where she has developed the pharmacoeconomics coursework and is a preceptor for MD/MPH students completing their MPH practicums. She is also Full Adjunct Professor, Div. of Social Sciences, at Long Island University College of Pharmacy and Health Sciences, including as a preceptor for students completing rotations in health outcomes and pharmacoeconomics. Dr. Arnold is a founding member of the International Society for Pharmacoeconomics and outcomes Research (ISPOR) and is an author/coauthor of numerous articles and book chapters in the areas of pharmacology, pharmacoeconomics and cost containment strategies. As Dr. Renee Arnold has adjunct faculty positions at several institutions (Mount Sinai, LIU) and has led multiple US-government, as well as commercially-funded studies, she is well qualified to provide a mutually supportive interaction between scientists conducting clinical research.

If you are interested in supporting our clinical study, please contact Allison Moore at [email protected].

Learn more on this topic

Related Blog Posts

Hot Off the Press – Potential Treatment for CMT1A

Two recent publications from Pharnext describe a novel synergistic combination of 3 drugs (baclofen, naltrexone and sorbitol) and its effect on CMT1A both in the lab and in a phase II clinical trial. These 3 drugs already approved but for unrelated conditions, are combined at new optimal lower doses and under a new formulation. This novel potential therapeutic is called PXT-3003.

Support CMT Therapeutic Alliance

HNF has entered into a joint venture – the CMT Therapeutic Alliance – with a unique non profit organization (BioPontis Alliance for Rare Diseases) that brings professional drug discovery capabilities to translate our research results into potential treatments.

Sneak Peak of Fall Newsletter: CMT Research Study Survey

My name is Elizabeth Francisco and I am a graduate student from the Genetic Counseling program at the University of North Carolina Greensboro. I am inviting you to participate in a research study. The goal of my study is to learn more about the experiences of people with Charcot-Marie-Tooth (CMT) with genetic counseling and genetic testing. Adults with CMT and parents or legal guardians of someone of any age who has a diagnosis of CMT are eligible to participate

Building Awareness on CMT and Supporting the Patient Community – HNF Announces Support from Pharnext

HNFpharnext recently entered into a partnership with the French biopharmaceutical company, Pharnext, to help raise awareness of Charcot-Marie-Tooth (CMT) disease and support the CMT patient community through several initiatives. Building awareness is key! Pharnext’s support will assist HNF in distributing HNF’s CMT Update quarterly newsletter, enhancing the Global Registry for Inherited Neuropathies (GRIN), setting up activities for CMT September Awareness Month in the US and strengthening the CMT Inspire Community.

Help us answer questions that your doctors and the CMT Research Community aren’t too sure about.

Did you know that you can become part of a community in therapy development and further research for all forms of CMT and inherited neuropathies? The mission of the Global Registry for Inherited neuropathies (GRIN) is to collect clinical and genetic information from patients with ALL forms of Charcot-Marie-Tooth (CMT) and other related rare and ultra rare inherited neuropathies.

Hot off the press

It seems like almost weekly there is another new publication on CMT with interesting basic biology. While an earlier “Hot off the press” highlighted the work of Cherry and co-workers at the University of Texas Southwestern Medical Center who showed show that neurons lacking a gene for rab7 result in neuropathy.

New Study on CMT Type 2B

If we are to learn more about CMT and the effectiveness of rehabilitation it is worth asking the patient and their caregiver. A recent Italian study by Padua et al recently described a survey of CMT patients and caregivers and their perspectives and perceptions of rehabilitation efficacy and needs.

Allison Moore is going to be published!

HNF’s CSO (Chief Scientific Officer), Sean Ekins wrote a blog about his work with Allison Moore and her two “fighter Mom” friends Lori Sames and Jill Wood. He named his blog: “Rare disease heroes – Extraordinary collaborators we should be listening too.” Sean helped my friends and I write a paper called: “Multifaceted roles of ultra rare and rare disease patients/parents in drug discovery.” YES, Allison Moore is going to be published! It will be in Drug Discovery Today, soon. The link to the reprint is below.

Join the conversation

Leave a Comment

4 Comments

  1. Tristen Chernove

    I have CMT and am interested in participating in trials. I have been very active and fit all my life (now 39 years old), competing at the world level in paddlesports, representing Canada at two World Championships. I now cycle somewhat competitively as I want to use my legs as much as I can, while I still can.

    Reply
    • courtney

      Please take 30 minutes of your time and register for the Global Registry for Inherited Neuropathies and you will be contacted for any upcoming trials. https://www.hnf-cure.org/registry/

      Reply
  2. Tammy

    I have CMT, female n 50 yrs old. Live in Baltimore Maryland

    Reply
  3. Kena Gottier

    I have CMT and am interested in participating in any open trials and/or studies.

    Reply

Submit a Comment

Your email address will not be published. Required fields are marked *

Newsletter

Join for notifications on events, campaigns, & news